AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00843349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 900 mg Phosphate Diet
Description: Amount of phosphorus consumption in a day kept below 900 mg.
Study NCT00843349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LC Placebo
Description: Placebo for Lanthanum Carbonate
Study NCT00843349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LC Placebo
Description: Placebo for Lanthanum Carbonate
Study NCT00843349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ad Libitum Diet
Description: Patients continued to eat their usual diet.
Study NCT00843349 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ad Libitum Diet
Description: Patients continued to eat their usual diet.
Study NCT00980876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cipro HC
Description: Cipro HC (Ciprofloxacin HCl and Hydrocortisone)
Study NCT00980876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin HCl and Hydrocortisone
Description: Ciprofloxacin Hydrochloride and Hydrocortisone
Study NCT00089648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment for approximately 1 year or until disease progression/unacceptable toxicity; after completion of 1 year, pts with clinical benefit can continue the study treatment in a separate continuation protocol
Study NCT01454752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent parasite clearance
Description: Sulphadoxine-pyrimethamine (500/25mg) according to age, given on day 1; Amodiaquine (200mg) according to age, given daily for 3 days
Study NCT01454752 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, similar in appearance and taste to active treatment, given daily over 3 days
Study NCT03515408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: The 10-Hz stimulation is delivered at 100% of the subject's resting motor threshold via 60 trains of 3-s 10-Hz rTMS (30 pulses with 27-s duration per train).
Study NCT03515408 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: The 10-Hz stimulation is delivered at 100% of the subject's resting motor threshold via 60 trains of 3-s 10-Hz rTMS (30 pulses with 27-s duration per train).
Study NCT00420745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix™
Description: Two-dose oral vaccination.
Study NCT00420745 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two-dose oral administration
Study NCT00300053 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLBS14 (low-dose)
Description: Eligible subjects will receive subcutaneous injections of 5 µg/kg/day G-CSF for 5 days to mobilize CD34+ cells from the bone marrow to the peripheral blood. Mononuclear cells (MNCs) will be collected via apheresis on day 5. On the day of the cell/placebo injection (day 6), the apheresis product will be enriched for CD34+ cells using the Isolex 300i Magnetic Cell Selection System (Baxter Healthcare). Autologous CD34+ cells will be delivered in 10 intramyocardial injections of 0.2 mL at a dose of 1 x 10\^5 (=100000) cells/kg bodyweight each using the MyoStar injection catheter (Biosense Webster, Inc.) into the target areas of myocardial ischemia.
Study NCT00300053 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLBS14 (high-dose)
Description: Eligible subjects will receive subcutaneous injections of 5 µg/kg/day G-CSF for 5 days to mobilize CD34+cells from the bone marrow to the peripheral blood. Mononuclear cells (MNCs) will be collected via apheresis on day 5. On the day of the cell/placebo injection (day 6), the apheresis product will be enriched for CD34+ cells using the Isolex 300i Magnetic Cell Selection System (Baxter Healthcare). Autologous CD34+ cells will be delivered in 10 intramyocardial injections of 0.2 mL at a dose of 5 x 10\^5 (=500000) cells/kg bodyweight each using the MyoStar injection catheter (Biosense Webster, Inc.) into the target areas of myocardial ischemia.
Study NCT00300053 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection
Description: Eligible subjects will receive subcutaneous injections of 5 µg/kg/day G-CSF for 5 days to mobilize CD34+ cells from the bone marrow to the peripheral blood. Mononuclear cells (MNCs) will be collected via apheresis on day 5. On the day of the cell/placebo injection (day 6), the apheresis product will be enriched for CD34+ cells using the Isolex 300i Magnetic Cell Selection System (Baxter Healthcare). Placebo will be delivered in 10 intramyocardial injections of 0.2 mL each of 0.9% NaCl (saline) in 5% autologous plasma into the target areas of myocardial ischemia.
Study NCT01787838 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Focused Health Education
Description: A two-phase quality improvement study was designed to modify staff and patient behaviors. The project incorporated evidence-based strategies of staff education, feedback and incentives for performance and patient education.~The staff received monthly feedback on departmental immunization rates, and incentives for performance. A one-page patient education flyer, written at 3rd grade reading level, was added to encourage patients to inquire about it.
Study NCT02101567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head
Description: In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute after delivery of the head in cesarean section.
Study NCT02101567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin 5 IU iv infusion and Methtergine 0.2 mg iv
Description: In the second group of patients oxytocin 5 IU will be given iv infusion and Methergine 0.2 mg iv
Study NCT03226587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blue light
Description: Subjects will be exposed to blue light (453 nm wavelength) for 30 minutes
Study NCT03226587 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: control exposure
Description: Subjects will get control exposure to 30 minutes of whole body, which causes only comparable warming of skin as with blue light exposure.
Study NCT03963440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Adherence Rating Scale (EARS)
Description: Inclusion and first questionnaires period (10 questionnaires), after geting consent, during normal patient consultation schedule for functional restoration program of the lumbar spine (1 to 3 weeks hospital in day care).~Second questionnaire period at 48h (Only EARS questionnaire) Third questionnaires period (10 questionnaires) at the end of the restoration program hospital care.~Fourth and last questionnaires period (10 questionnaires) at 3 months during a normal patient follow-up consultation No additional appointments.
Study NCT02934594 — intervention group
Intervention type: OTHER
Intervention: Palliative Decompression
Description: palliative decompression to MSCC patients: before motor deficit (Group A), within 48 hours after motor deficit (Group B1), 48 hours after motor deficit (Group B2)
Study NCT02295059 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega 3 fatty acids
Description: supplied as soft gelatin capsules for oral administration
Study NCT03920800 — intervention group
Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Data extraction from medical files
Study NCT03920800 — intervention group
Intervention type: BIOLOGICAL
Intervention: Immunohistochemistry
Description: Immunohistochemistry with Ki67 and p16 antibodies on residual samples, if this had not been foreseen in the standard of care management of the patient.
Study NCT04159376 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: All patients will have a PET/CT and PET/MR study performed at the same clinical setting using a single dose of tracer administration.~The study cohort includes 150 patients 18 years or older, having metastatic skeletal involvement on baseline PET/CT prior to treatment. Baseline studies and follow up studies of the patients referred post treatment, will be reviewed.~The tracers will be FDG, labelled PSMA labelled Somatostatin and F-DOPA in order to assess skeletal lesions detection of all tumor types.~Skeletal lesions will be divided into marrow-based lesions, lytic, blastic and scleroric lesions. Tracer uptake will be measured at baseline and after treatment. Metabolic PET parameters, CT appearance and MR parameters will be assessed.~The best MR-based attenuation algorithm for detection of lesions and monitoring response will be derived.
Study NCT00197743 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A + Beta Carotene
Description: one daily oral dose of 30 mg beta-carotene + 5000 IU preformed vitamin A
Study NCT00197743 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamins
Description: one daily oral dose of 20 mg thiamine (vitamin B-1), 20 mg riboflavin (vitamin B-2), 25 mg vitamin B-6, 100 mg niacin, 50 ug cobalamin (vitamin B-12), 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic acid
Study NCT00197743 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill
Study NCT02295137 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Using pre-procedural CTA to guide advanced EVAR procedure
Study NCT04192682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle, Combined With Sintilimab 200mg/time，21-day cycle。
Study NCT01991314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate
Description: 200mg tablets.
Study NCT02472405 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 595/1064nm Multiplex Laser
Description: The multiplex cynergy laser will be used for this study. A third of the scar will solely be treated with the 595nm PDL.
Study NCT02472405 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 595nm PDL
Description: One third of the scar will be treated with 595nm PDL solely for 3 weeks (1 treatment session per week).
Study NCT04146701 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: venous blood withdraw (ca. 40ml)
Study NCT01409473 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prostate SBRT with concurrent boost to intraprostatic lesion(s)
Description: 40 Gy in 5 fractions to prostate for low-risk and 45 Gy in 5 fractions to prostate for intermediate-risk patients, and 50 Gy in 5 fractions to intraprostatic lesion(s), delivered over 10-14 days on preferably every other day.
Study NCT00409825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-OHPC
Description: Intra-muscular injection of 250 mg 17-OHPC administered weekly between the second and third trimesters of pregnancy, until time of delivery.
Study NCT00409825 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draws
Description: 10 cc of blood will be drawn prior to the fifth weekly administration of 17-OHPC during second trimester of pregnancy, and then once daily for seven consecutive days post-dose. 10 cc of blood also will be drawn prior to weekly administration of 17-OHPC from sixth weekly dose in the second trimester until the last scheduled dose in the third trimester. Prior to this last scheduled dose, 10 cc of blood will be drawn, as well as once daily for seven consecutive days post-dose.
Study NCT03391895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home based exercise program
Description: Program will include deep diaphragmatic breathing exercises, local expansion exercise on the collapsed areas in scoliosis concave sides with elastic exercise bands, dynamic lumber stabilization exercises for core stabilisation, strengthening of interscapular muscles with elastic bands and stretching exercises for lumbar extensor, hip flexor and hamstring muscles. Exercises will be applied 2 sets of 10 repetitions and once a day.
Study NCT03391895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home based exercise program
Description: Program will include deep diaphragmatic breathing exercises, local expansion exercise on the collapsed areas in scoliosis concave sides with elastic exercise bands, dynamic lumber stabilization exercises for core stabilisation, strengthening of interscapular muscles with elastic bands and stretching exercises for lumbar extensor, hip flexor and hamstring muscles. Exercises will be applied 2 sets of 10 repetitions and once a day.
Study NCT03391895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure after assessment of respiratory muscle strength for each patient every week.
Study NCT00751127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PhXA41
Description: One drop in the affected eye once daily for six months.
Study NCT00751127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol
Description: One drop in the affected eye twice daily for six months.
Study NCT03098979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (BAY1067197)
Description: 5 mg orally once daily for 20 weeks
Study NCT03098979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (BAY1067197)
Description: 10 mg orally once daily for 20 weeks
Study NCT03098979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (BAY1067197)
Description: 20 mg orally once daily for 20 weeks
Study NCT03098979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (BAY1067197)
Description: 30 mg orally once daily for 20 weeks
Study NCT03098979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (BAY1067197)
Description: 40 mg orally once daily for 20 weeks
Study NCT03098979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally once daily for 20 weeks
Study NCT00674726 — intervention group
Intervention type: OTHER
Intervention: Observation and measurement of axilo-rectal temperature
Description: Measurement of axilo-rectal temperature
Study NCT04719559 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Laser-assisted drug delivery
Description: All patients received treatment using the same protocol with the same fractional ablative carbon dioxide laser (eCO2 PlusTM, manufactured by Lutronic, South Korea). Each patient was applied with Lidopin 5% cream (Panion \& BF Biotech Inc.), which remained on the scar for 30 min for pain relief before each laser course. Later, the Lidopin 5% cream was gently removed using a normal saline-rinsed gauze, and the scar was treated with a fractional ablative carbon dioxide laser with two passes under a 10,600 nm wavelength, 120 mm spot size, pulse energy of 50 mJ, 30 W of power, and a density of 200. A topical steroid cream (clobetasol propionate, 0.05%) was evenly applied on the scar gently back and forth using a cotton swab immediately after the laser treatment. The patients underwent five full courses by the same doctor according to the same protocol, with each course given 4 weeks apart.
Study NCT03526705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NB-UVB
Description: Phototherapy
Study NCT02661308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Litebook
Study NCT02661308 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Litebook
Study NCT00838851 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clinical Center Reference Endotoxin (CCRE)
Description: Inhalation of 20,000 EU Clinical Center Reference Endotoxin (CCRE)
Study NCT05764499 — intervention group
Intervention type: OTHER
Intervention: Physiotherapy Scoliosis Specific Exercise (PSSE)
Description: Patients completed 120 hours of group based PSSE over a four week time frame. Monday - Friday, 10.00-17.00.
Study NCT00442793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin beta
Description: As prescribed, 3 times weekly
Study NCT00442793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: 0.4 micrograms/kg iv every 2 weeks
Study NCT00793975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-1121B
Description: Cohort 1~2 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.
Study NCT00793975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1121B
Description: Cohort 2~4 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.
Study NCT00793975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1121B
Description: Cohort 3~6 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.
Study NCT00793975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1121B
Description: Cohort 4~8 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.
Study NCT00793975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1121B
Description: Cohort 5~10 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.
Study NCT00793975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1121B
Description: Cohort 6~13 mg/kg once a week for 4 weeks, followed by a 2-week observation period.
Study NCT00793975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1121B
Description: Cohort 7~16 mg/kg once a week for 4 weeks, followed by a 2-week observation period.
Study NCT03626896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviFUS System
Description: BBB Disruption by FUS in recurrent GBM Other Name: Neuronavigation-guided focus ultrasound system
Study NCT03259893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AliveCor mobile ECG cardiac monitor
Description: AliveCor mobile ECG cardiac monitor is capable of providing real-time heart telemetry using a smart phone. Participants will be instructed to transmit rhythm data twice weekly and during symptomatic AF.
Study NCT03259893 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AliveCor mobile ECG cardiac monitor
Description: AliveCor mobile ECG cardiac monitor is capable of providing real-time heart telemetry using a smart phone. Participants will be instructed to transmit rhythm data twice weekly and during symptomatic AF.
Study NCT03259893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AF Program
Description: The AF program includes a bundle of sub-interventions that target specific AF risk factors including hypertension, obesity, physical inactivity, sleep hygiene, and smoking. Participants randomized to the intervention group 2 will undergo counseling by the nurse and guided through the structured, goal-directed AF program. Each participant will receive an AliveCor cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
Study NCT03259893 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Guideline-directed medical therapy according to clinical standard practice at Boston Medical Center.
Study NCT01603602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: Intramuscular injections of botulinum toxin Type A into specified muscles of the upper limb on Day 1.
Study NCT01603602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (Placebo)
Description: Intramuscular injections of normal saline (placebo) into specified muscles of the upper limb on Day 1.
Study NCT02880423 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tubal ligation group II
Description: Every woman , who is eligible to enter the study in terms of the above criteria , will receive a detailed explanation of the study and will review the consent form , and then be asked whether she agrees to participate in . If so , the participant will stamped on the informed consent form .~The control group will be women who undergo tubal ligation method BTL during cesarean section . All women will be invited to follow up about three months after surgery. The women will answer questionnaire to quantify the symptoms of menopause by NAMS , blood test for AMH and sonar and Doppler examination of both the ovaries
Study NCT02880423 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: salpingectomy group I
Description: women who agreed to participate in the study and assigned randomly to this group will have salpingectomy during cesarean section for sterilization.
Study NCT02641054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVXL-0107
Study NCT02641054 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CVXL-0107
Study NCT02641054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02641054 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02641054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa
Study NCT02641054 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levodopa
Study NCT04017377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Cisplatin; nab-paclitaxel
Description: Drug: Paclitaxel for Injection（Albumin Bound). Other Name: Ke ai li, ZhusheyongZishanchun(Baidanbai Jiehexing)
Study NCT02202252 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insertion of a single drain
Description: A negative pressure drain will be inserted below the lower flap directing to the axilla.